Vcanbio Cell & Gene Engineering Balance Sheet Health
Financial Health criteria checks 6/6
Vcanbio Cell & Gene Engineering has a total shareholder equity of CN¥3.7B and total debt of CN¥40.8M, which brings its debt-to-equity ratio to 1.1%. Its total assets and total liabilities are CN¥5.3B and CN¥1.6B respectively. Vcanbio Cell & Gene Engineering's EBIT is CN¥139.2M making its interest coverage ratio -5. It has cash and short-term investments of CN¥1.4B.
Key information
1.1%
Debt to equity ratio
CN¥40.76m
Debt
| Interest coverage ratio | -5x |
| Cash | CN¥1.44b |
| Equity | CN¥3.68b |
| Total liabilities | CN¥1.60b |
| Total assets | CN¥5.28b |
Recent financial health updates
Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
Aug 26
Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
May 24Recent updates
Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Popularity With Investors Is Under Threat From Overpricing
Sep 27Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
Aug 26Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
May 24Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Are Actually Better Than They Appear
May 02Subdued Growth No Barrier To Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Price
Apr 24Financial Position Analysis
Short Term Liabilities: 600645's short term assets (CN¥2.5B) exceed its short term liabilities (CN¥1.5B).
Long Term Liabilities: 600645's short term assets (CN¥2.5B) exceed its long term liabilities (CN¥118.8M).
Debt to Equity History and Analysis
Debt Level: 600645 has more cash than its total debt.
Reducing Debt: 600645's debt to equity ratio has reduced from 3.3% to 1.1% over the past 5 years.
Debt Coverage: 600645's debt is well covered by operating cash flow (713.3%).
Interest Coverage: 600645 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 08:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vcanbio Cell & Gene Engineering Corp., Ltd is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bin Wu | Founder Securities Co., Ltd. |
| Ye Hui Yang | Huatai Research |
| Ban Wang | Minsheng Securities Co. |